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Human herpes virus-6 (HHV-6) was first isolated from peripheral
blood leucocytes of patients with lymphoproliferative disorders,
including lymphoma and leukaemia (Salahuddin et al, 1986).
HHV-6 is predominantly a CD4+ T-lymphotropic virus, although
other cell types such as B and CD8+ T-lymphocytes, mono-
cytes/macrophages, megakaryocytes and natural killer (NK) cells
can be infected in vitro (Ablashi et al, 1988a; Braun et al, 1997).
As for other herpesviruses, primary infection occurs mainly in
childhood, being the causative agent of exanthem subitum (Braun
et al, 1997). HHV-6 probably remains latent in the host after
primary infection since it can be reactivated in immunocompro-
mised patients such as those receiving a bone marrow transplant or
those infected with HIV; such patients may present a broad spec-
trum of clinical disorders in response to infection ranging from
asymptomatic infection to illnesses such as interstitial pneumonia
or encephalitis (Ragona et al, 1995; Braun et al, 1997).
A role for HHV-6 in haematological malignancies, such as
lymphomas has been suggested, though it is primarily a lytic virus;
the transforming potential of its DNA has been demonstrated in
vitro (Razzaque, 1990). Genomic DNA and several subgenomic
clones from HHV-6 variant A can produce malignant transforma-
tion of NIH 3T3 cells and human keratinocytes (Razzaque, 1990;
Razzaque et al, 1993; Thompson et al, 1994). HHV-6 genome
integration has been found in peripheral blood mononuclear cell
DNA (Luppi et al, 1993) and HHV-6 DNA sequences have been
identified in the pathologic tissue of Hodgkin’s disease (Di Luca
et al, 1994), non-Hodgkin’s lymphoma (Di Luca et al, 1994) and in
peripheral blood mononuclear cells from patients with acute
lymphoblastic leukaemia (ALL) (Luka et al, 1991) and with T-cell
chronic lymphoproliferative disease (Braun et al, 1995).
In addition, HHV-6 seroprevalence was shown to be higher in
patients with Hodgkin’s disease or acute myeloid leukaemia
(AML) as compared with controls (Clark et al, 1990).
In the present study we investigated the relationship between
AML, ALL, chronic myeloid leukaemia (CML), refractory
anaemia with excess of blasts (RAEB) and HHV-6 antibody level
in a multicentre case-control study on risk factors for leukaemias
(Mele et al, 1994).
PATIENTS AND METHODS
This study was conducted in three Italian cities, Roma (central
Italy), Bologna and Pavia (northern Italy) between 1 November
1986 and 31 March 1990.
Recruitment of study subjects
The method of study subject recruitment and data collection is
described in detail elsewhere (Mele et al, 1994). Cases were 15
years of age or older with newly diagnosed AML, ALL, CML, or
RAEB. Diagnostic criteria were based on the revised French–
American–British classification of bone marrow aspirates for
acute leukaemias and RAEB; diagnosis for CML was based on
typical and cytogenetic laboratory features. Controls were
recruited during the study period among outpatients without
haematological malignancies and were seen in the same hospital
where cases were identified.
The control group was selected by taking the first five out-
patients in Rome and the first three in Bologna and Pavia seen on a
random day each week. Subjects who had received blood product
transfusions were excluded from the study.
A standard precoded questionnaire on medical history, behav-
ioural habits and environmental exposure was administered to
both cases and controls. Informed consent was obtained from all
study participants.
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All sera were stored at – 20°C and subsequently tested. Sera were
coded prior to laboratory analysis to ensure that investigators were
blind to the status of each sample. Coded sera were serially diluted
and tested for the presence of antibodies against HHV-6 by
indirect immunofluorescence assay (IFA) on HSB-2 cells infected
with HHV-6 (GS strain) as viral capsid antigen source (Ragona
et al, 1994). Mock infected cells were used to evaluate non-
specific background fluorescence. Antibody titres were deter-
mined by two independent investigators and expressed as the
highest serum dilution yielding detectable immunofluorescence on
an appreciable fraction of the antigen-positive cells.
Statistical analysis
Geometric mean titres (GMT) were computed for each group of
cases and compared with those of controls by the ratio and its 95%
confidence interval (CI). In calculating GMT, sera were consid-
ered negative at the lowest dilution as 1:10. Results were similar
when omitting negative sera from analysis. Multiple logistic
regression was used to estimate adjusted odds ratios (OR) and
95% CI for each case group as compared with controls. BMDP
software was used for all statistical analyses.
RESULTS
Serum samples from 450 out of 636 recruited cases and from 948 out
of 1193 recruited controls were tested. No differences regarding age,
sex, education and leukaemia type were observed between tested
and untested cases. Eighty-five controls and 74 cases who previously
received blood product transfusions (e.g. blood and pooled plasma
products) were excluded from the study. Thus, 386 cases enrolled at
the time of leukaemia diagnosis, and 853 controls aged 15 years or
older were included in this study. Iron deficiency and thalassaemia
minor accounted for 43% of control diagnoses; 36% of the control
group had no underlying haematological disorder.
In the control group, seropositivity at 1:80 serum dilution was
placed at 82 percentile (Table 1); therefore, sera with titres at
³ 1:80 were considered positive. The seroprevalence population
was 18.2%; seroprevalence of the cases were 15.1% (AML),
20.0% (ALL), 25.5% (RAEB) and 17.6% (CML).
Cases and controls from central Italy (Roma) displayed higher
seropositivity than cases and controls from northern Italy
(Bologna and Pavia). Differences in GMT were found according
to education level among controls, ALL and CML cases, whereas
no relation with age and sex was found (Table 2).
Multiple logistic regression analysis showed that only AML
presented significantly increased HHV-6 seropositivity as
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Table 1 Distribution of cases and controls by HHV-6 titre
Negative at
Titres 1:20 1:20 1:40 1:80 1:160 1:320 Total Geometric means
n (%) n (%) n (%) n (%) n (%) n (%) n titresa
Control 250 (29.3) 88 (10.3) 360 (42.2) 115 (13.5) 35 (4.1) 5 (0.6) 853 29.2
AML 39 (24.5) 15 (9.4) 65 (40.9) 23 (14.5) 12 (7.5) 5 (3.1) 159 35.0
ALL 16 (29.1) 3 (5.5) 25 (45.5) 5 (9.1) 5 (9.1) 1 (1.8) 55 32.3
RAEB 20 (34.5) 1 (1.7) 22 (37.9) 11 (19.0) 4 (6.9) 0 (0.0) 55 30.8
CML 31 (27.2) 18 (15.8) 45 (39.5) 10 (8.8) 8 (7.0) 2 (1.8) 114 29.9
aSera negative at the lowest dilution have been allocated a titre of 1:10. AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; RAEB, refractory
anaemia with excess of blasts; CML, chronic myeloid leukaemia.
Table 2 Distribution of cases and controls and geometric mean titres (GMT) by demographic characteristics
Control AML ALL RAEB CML
n GMT P
a n GMT P
a n GMT P
a n GMT Pa n GMT Pa
Age
15–19 41 30.0 8 40.0 12 31.8 0 – 1 10.0
20–29 194 30.4 19 33.3 14 40.0 1 10.0 7 44.2
30–39 159 30.8 0.580 20 33.6 0.693 7 32.8 0.876 2 20.0 0.064 20 28.3 0.558
40–49 131 29.6 25 27.9 3 31.8 3 10.0 18 30.5
³ 50 328 27.5 87 37.5 19 27.8 52 34.1 68 29.5
Sex
Male 313 29.5 0.749 75 31.2 0.212 22 29.2 0.513 36 31.2 0.895 71 28.1 0.355
Female 540 29.0 82 37.4 33 34.5 22 30.1 43 33.0
Study centre
North 353 27.1 0.001 71 35.6 0.797 31 26.7 0.181 25 25.2 0.057 37 26.4 0.032
Centre 500 32.5 88 34.2 24 37.4 33 40.0 77 38.5
Education level
Highb 311 31.6 0.045 44 33.6 0.937 17 47.1 0.040 9 31.8 0.988 27 21.1 0.020
Lowc 534 28.1 108 33.2 37 27.0 46 31.9 82 33.2
Total 853 29.2 159 35.0 55 32.3 58 30.8 114 29.9
aP for trend. b³ 9 years of schooling; c≤ 8 years of schooling. Abbreviations as in Table 1.compared with controls at higher serum dilutions (OR = 5.58, 95%
CI 1.40–22.3) (Table 3); similar results were obtained when GMT
ratios were analysed. In addition, the OR increased with increasing
seroreactivity in the IFA assay (P for trend = 0.022).
DISCUSSION
Our present study, the largest serological case-control investiga-
tion conducted on patients with haematologic malignancies who
had not yet undergone immunosuppressive chemotherapy, identi-
fied a slight significant association between increased HHV-6
seropositivity and GMT ratio with AML (P for trend = 0.022,
adjusted OR 1.20, 95% CI 1.07–1.33) respectively. The results
presented here are in agreement with those obtained in a case-
control study in which the prevalence of antibodies to HHV-6 in
AML patients was higher than in the control group: GMT = 2.66,
95% CI 1.90–3.74 (Clark et al, 1990). Furthermore, two cases of
monoblastic leukaemia were reported in which malignant cells
contained HHV-6 DNA, antigens and immature viral particles
(Krueger et al, 1994), whereas, in another study, HHV-6 DNA was
undetectable by blot hybridization in ten AML patients (Josephs et
al, 1988).
The negative results regarding an association between HHV-6
antibody titers and ALL, CML, or RAEB in the present study are
also consistent with the literature. Ablashi et al (1988b) found
higher levels of HHV-6 antibodies in a small group of children
with ALL as compared with normal subjects. However, Levine
et al (1992a) found no significant differences in antibody titers
between 50 patients with ALL and 50 blood donors. This last
finding suggests that the association previously reported for HHV-
6 and ALL was a result of the study population age, rather than a
true relationship.
Seroepidemiological evidence indicates that HHV-6 infection
(IgG antibody titres of > 1:20 by IFA) is common and widespread,
with a proportion of subjects ranging from 20% to 80% (Okuno et
al, 1989; Levy et al, 1990; Yanagi et al, 1990). In this study, 18.2%
of the control population and an average of 22.3% (range
15.1–25.9%) of the cases were seropositive at 1:80 serum dilution
by IFA. This positivity rate is actually lower than those previously
reported (Okuno et al, 1989; Levy et al, 1990; Yanagi et al, 1990;
Torelli et al, 1991). Furthermore, in Italy, Torelli et al (1991) found
antibodies against HHV-6 in 54% of 200 blood donors at a 1:40
serum dilution. The differences found in HHV-6 seroprevalence
may result from the use of different serological assays and criteria
of positivity. The majority of the epidemiological studies were
performed with IFA, but the limiting titre for seropositivity varied.
The limiting titre adopted in this study was 80, which includes
82% of the control population.
Other factors that may account for differences in HHV-6 sero-
prevalence include the definition of the control population: there is
a possibility that HHV-6 is transmitted by the transfusion of blood
or blood components (Wilborn et al, 1994). We excluded those
patients who received blood product transfusions from both cases
and controls. The possibility that differences in antibody titres
could be detected using different isolates remains to be investi-
gated. In a previous study on HHV-6 infection in Italy no varia-
tions in seroprevalence or in antibody GMT were observed
assaying the sera against the strains G.S., U1102, or Z29 infected
cells (Ragona et al, 1994).
Several studies conducted in healthy individuals showed that
HHV-6 seroprevalence can be influenced by age, sex and
geographic/ethnic origin, titres being higher in children than in
adults, in females than in males and Ghanaians compared with
Asians and White Americans (Levine et al, 1992b; Ragona et al,
1994; Braun et al, 1997). In our study no differences in seroposi-
tivity were observed on the basis of age or sex.
In cancer patients, therapy may play a role in antibody titres,
and the high levels of HHV-6 antibody may be a result of therapy
rather than relating to the neoplastic disease. The possibility of
reactivation of HHV-6 infection by therapy-induced immunosup-
pression can be excluded because sera were drawn at the time of
diagnosis, i.e. well before chemotherapy was administered. In
addition, none of the cases studied here had received previous
treatments for past malignancies. Furthermore, IFA reactivity was
not elevated among cases, as might be expected if there was a
general activation of HHV-6 infection. However, because the
comparison was performed between values obtained at 1:80 and
higher serum dilutions, we conclude that the titre of anti-HHV-6
antibodies and not the frequency of infection is significantly
higher in AML individuals than in control subjects. This finding is
not clear; however, serology data indicated that immune system of
AML patients is activated against HHV-6 antigens. Furthermore,
the serological assays currently used for identifying HHV-6 infec-
tion do not differentiate between persistent, latent or active
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Table 3 Odds ratiosa by HHV-6 titreb, P for trend and GMT ratios in cases and controls
GMT ratios in
Titres 1:80 1:160 1:320 P for trend cases and
controls
Control 1.00 1.00 1.00 1.00
AML 1.04 1.56 5.58 0.022 1.20
(0.61–1.75) (0.74–3.29) (1.40–22.3) (1.07–1.33)
ALL 0.61 2.47 3.76 0.121 1.11
(0.23–1.61) (0.90–6.82) (0.41–34.9) (0.99–1.24)
RAEBc 1.62 1.64 – – 1.05
(0.77–3.43) (0.52–5.21) (0.94–1.18)
CML 0.67 1.89 4.92 0.102 1.02
(0.32–1.38) (0.82–4.35) (0.85–28.5) (0.92–1.14)
aAdjusted for sex, age (five groups), study centre and instruction. bTitres ≤ 40 have been used as reference group. cFour groups of age. Abbreviations as in
Table 1.infections. Detection of HHV-6 DNA in serum or plasma has been
shown to be a marker of active infection (Secchiero et al, 1995),
but does not clarify if HHV-6 has a possible casual role or viral
reactivation is triggered by the illness itself. In conclusion, a slight
significant association between HHV-6 antibody titres and AML
patients not previously treated was observed, while no significant
association was found between HHV-6 antibodies and ALL,
RAEB, or CML. Further studies should be performed to further
explore the relationship between HHV-6 infection and AML
leukaemias.
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